|
|
|
|
|
|
|
23.01.26 - 14:03
|
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock (GlobeNewswire EN)
|
|
|
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced underwritten registered direct offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for net proceeds of $20.85 million, after deducting commissions and other estimated offering expenses payable by Ocugen. The financing was led by RTW Investments, with additional participation from new and existing investors....
|
|
|
|
|
|
|
21.01.26 - 14:36
|
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock (GlobeNewswire EN)
|
|
|
MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for gross proceeds of $22.5 million, before deducting commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about January 22, 2026, subject to the satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by Ocugen. The financing is being led by RTW Investments, with additional participation from new and existing investors....
|
|
|
|
|
|
|
|
|
|
|
|
|
09.01.26 - 13:06
|
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference (GlobeNewswire EN)
|
|
|
MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will present at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026, at The Westin St. Francis in San Francisco, CA.“Year over year, Ocugen's presence at the JPM Healthcare Conference has evolved and we are delighted to share the potential of our modifier gene therapy platform along with clinical development progress,” said Dr. Musunuri. “This premier conference is the optimal way to kick off Ocugen's catalyst-rich 2026 and engage in critical conversations with potential strategic partners and the investment community.”In addition to Dr. Musunuri's session, members of Ocugen's executive team will be on site in San Franciso all week to conduct one-on-one meetings highlighting the Company's business strate...
|
|
|
|
|
10.12.25 - 15:24
|
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit (GlobeNewswire EN)
|
|
|
MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present at the Oppenheimer Movers in Rare Disease Summit taking place at the Sofitel New York on Thursday, December 11, 2025.“For the second year in a row, we will join leaders advancing groundbreaking discoveries for rare disease at this significant meeting,” said Dr. Musunuri. “I look forward to sharing more about Ocugen's novel modifier gene therapy platform with a gene-agnostic approach that has the potential to treat the entire disease and in turn large patient populations—in both rare and age-related blindness diseases.” Details regarding the fireside chat are as follows:Title: Fireside Chat with Aldeyra and Ocugen: Setting Sights on Inherited Retinal DystrophiesDate: Thursday, December 11, 2025Location: Second Floor Ballroom, Track ...
|
|
|
20.11.25 - 13:03
|
Ocugen CEO to Present at NobleCon21—Noble Capital Markets′ Twenty-First Annual Emerging Growth Equity Conference (GlobeNewswire EN)
|
|
|
MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen will present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex in Boca Raton, FL....
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
